written by reader Mannkind MNKD

By Anonymous Questions, February 26, 2015

Could the good Dr. comment on Mannkind, now that it’s Affrezza insulin inhaler is now on the market. I’m of the opinion that this could be a game changer, particularly for those who just can’t stand the thought of daily needles.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments
February 27, 2015 9:56 am

Afrezza is a rapid acting insulin–ie, for meal times for diabetics. Most people also use a basal (long-acting insulin) as well, which is only available as an injection. Granted, this would cut down to one-two injections per day, versus at every meal. So, the daily needle has not gone away, although the development of an inhaled long acting insulin might be a possibility. Also, this would be limited to those patients who do not have asthma, COPD, etc.

👍 10
February 27, 2015 12:19 pm

Nobody wants it, niche product at absolute best. The needles are so small now days in pens that there is nothing to be afraid of. Hate MNKD, Alfred will go down the tubes on this one UNLESS……… he can license the delivery technology, that is the true key. Not Insulin.

👍 236

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info